BBOT — BridgeBio Oncology Therapeutics, Inc.

BridgeBio Oncology Therapeutics, Inc. (BBOT) is a biotechnology company listed on NASDAQ. It is led by Pedro J. Beltran M.D., Ph.D., based in 256 East Grand Avenue, South San Francisco, CA, United States, 94080, with about 106 employees. BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.

Net income was -$44.8M. BBOT currently screens at market cap $610.4M.

Use this BBOT page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the BBOT quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the BBOT SEC filings page. Lician reads the product cache first so this HTML stays unique to BridgeBio Oncology Therapeutics, Inc. even when a live quote feed is slow.